ZITUVIMET XR
Clinical safety rating: caution
Comprehensive clinical and safety monograph for ZITUVIMET XR (ZITUVIMET XR).
Zituvimet XR (sitagliptin/metformin) is a combination of a dipeptidyl peptidase-4 (DPP-4) inhibitor (sitagliptin) and a biguanide (metformin). Sitagliptin increases incretin levels (GLP-1, GIP), enhancing insulin secretion and decreasing glucagon secretion. Metformin decreases hepatic glucose production, decreases intestinal absorption of glucose, and improves insulin sensitivity by increasing peripheral glucose uptake and utilization.
| Metabolism | Sitagliptin: primarily excreted unchanged in urine; metabolism is minor via CYP3A4 and CYP2C8. Metformin: not metabolized; excreted unchanged in urine via tubular secretion. |
| Excretion | Renal: sitagliptin ~79% unchanged in urine; metformin ~90% unchanged in urine via tubular secretion. Biliary/fecal: minimal. |
| Half-life | Sitagliptin: 12.4 h (prolonged in renal impairment); metformin: 6.2 h (prolonged in renal impairment). Clinically, twice-daily dosing for immediate-release, but ZITUVIMET XR is once-daily. |
| Protein binding | Sitagliptin: 38% bound (mainly albumin); metformin: negligible (<5% bound). |
| Volume of Distribution | Sitagliptin: 0.4 L/kg; metformin: 1.1 L/kg (high, indicating extensive tissue distribution; metformin accumulates in erythrocytes and GI tract). |
| Bioavailability | Sitagliptin: 87% (oral); metformin: ~55% (oral, decreased in extended-release vs immediate-release, with plasma Cmax delayed). |
| Onset of Action | Oral: sitagliptin DPP-4 inhibition within 1-2 h; metformin glucose-lowering within 2-3 h (single dose). |
| Duration of Action | Sitagliptin: 24 h (once-daily dosing); metformin: ~24 h (extended-release formulation provides sustained glucose lowering). Clinical note: effect persists beyond half-life due to mechanism. |
| Molecular Weight | 165.6 Da (metformin) + 195.5 Da (sitagliptin) - note Zituvimet XR is a combination; the active components have molecular weights of 165.6 Da (metformin) and 195.5 Da (sitagliptin). |
Initial: 1000 mg (2 tablets) orally once daily with the evening meal. Titrate based on efficacy and tolerability. Maximum daily dose: 2000 mg (4 tablets).
| Dosage form | TABLET, EXTENDED RELEASE |
| Renal impairment | eGFR 30-59 mL/min: Maximum dose 1000 mg daily; eGFR <30 mL/min or dialysis: Contraindicated. |
| Liver impairment | No specific adjustment recommended; use with caution in severe hepatic impairment (Child-Pugh class C) due to limited data. |
| Pediatric use | Safety and efficacy not established in pediatric patients <18 years. |
| Geriatric use | Initiate at low end of dosing range due to age-related renal impairment; monitor renal function closely. |
| 1st trimester | Avoid due to potential teratogenic effects (animal data show fetal toxicity). Use only if benefit outweighs risk. |
| 2nd trimester | Use only if clearly needed; monitor for fetal growth and amniotic fluid volume as metformin may cause fetal acidosis. |
| 3rd trimester | Avoid in third trimester due to risk of neonatal hypoglycemia and lactic acidosis; metformin crosses placenta and can accumulate in fetus. |
Clinical note
Comprehensive clinical and safety monograph for ZITUVIMET XR (ZITUVIMET XR).
| Placental transfer | Metformin actively crosses the placenta via organic cation transporters; fetal plasma concentrations can reach maternal levels. Evidence from human studies confirms placental transfer. |
| Breastfeeding | Metformin is excreted into breast milk in small amounts; no adverse effects reported in infants. Monitor infant for hypoglycemia, diarrhea, and lactic acidosis. Consider benefits of breastfeeding vs. potential risks. |
■ FDA Black Box Warning
Lactic acidosis: Metformin-associated lactic acidosis (MALA) is a rare but serious complication. Risk factors include renal impairment, concomitant use of certain drugs (e.g., topiramate, acetazolamide), age ≥65 years, radiological studies with contrast, surgery, acute conditions (e.g., dehydration, severe infection), hepatic impairment, and alcohol intake. Discontinue metformin if lactic acidosis is suspected.
| Serious Effects |
Hypersensitivity to metformin or sitagliptinSevere renal impairment (eGFR < 30 mL/min/1.73 m²)Acute or chronic metabolic acidosis including diabetic ketoacidosisLactic acidosis (history or risk factors)
| Precautions | Lactic acidosis risk (see black box warning), Renal impairment: contraindicated if eGFR <30 mL/min/1.73 m²; not recommended if eGFR 30-45; assess renal function before initiation and periodically, Hypoglycemia: when used with insulin or insulin secretagogues, Pancreatitis: acute pancreatitis reported; discontinue if suspected, Heart failure: sitagliptin associated with heart failure risk; monitor, Hypersensitivity reactions: including Stevens-Johnson syndrome, Vitamin B12 deficiency: metformin may decrease B12 levels, Acute alcohol intoxication: warn against excessive alcohol intake, Iodinated contrast: discontinue metformin prior to or at time of imaging; restart after 48 hours if renal function stable |
Loading safety data…
| Lactation Rating | L2 (Safer) |
| Teratogenic Risk | ZITUVIMET XR (sitagliptin/metformin extended-release) is contraindicated in the second and third trimesters due to metformin-associated lactic acidosis risk; limited human data for sitagliptin suggest low teratogenic risk. First trimester exposure: No evidence of major malformations in animal studies, but human data insufficient. |
| Fetal Monitoring | Monitor maternal renal function, blood glucose, and lactic acid levels. Assess fetal growth and amniotic fluid volume via serial ultrasound. Monitor for neonatal hypoglycemia if used near term. |
| Fertility Effects | Metformin may improve ovulatory function in women with polycystic ovary syndrome (PCOS), potentially enhancing fertility. Sitagliptin has no known adverse effects on fertility. |
| Food/Dietary | Decreased efficacy if taken with high-fat meal? No specific interaction documented; take with evening meal to mitigate GI side effects. Avoid excessive alcohol (>3 drinks/day) due to increased risk of metformin-associated lactic acidosis. No grapefruit interaction known. |
| Clinical Pearls | ZITUVIMET XR is a combination of sitagliptin (DPP-4 inhibitor) and metformin (biguanide) in an extended-release formulation. Avoid in patients with eGFR <30 mL/min/1.73 m²; assess renal function before initiation and periodically. Monitor for lactic acidosis (rare but fatal)—discontinue if serious infection, dehydration, or contrast dye exposure. Sitagliptin may cause acute pancreatitis; discontinue if abdominal pain with nausea/vomiting. Metformin reduces vitamin B12 absorption; check levels in anemia or neuropathy. Titrate slowly to minimize GI upset; take with evening meal to improve tolerability. |
| Patient Advice | Take ZITUVIMET XR exactly as prescribed, once daily with the evening meal to reduce stomach upset and ensure proper extended-release effect. · Do not crush, chew, or split the tablet; swallow whole to avoid dose dumping. · Monitor blood sugar as directed; notify your healthcare provider if you experience unexplained nausea, vomiting, abdominal pain, or severe weakness. · Avoid excessive alcohol intake while taking this medication; it increases the risk of lactic acidosis. · Tell your doctor immediately if you develop symptoms of pancreatitis (severe stomach pain that may radiate to your back, with vomiting) or an allergic reaction (rash, swelling, trouble breathing). |